肿瘤细胞治疗研究
英文原题：Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting.
双特异性抗体（BsAbs）和双靶向CAR-T（CAR T）细胞在过去几年中已被用于复发/难治性多发性骨髓瘤（RRMM）患者，因为越来越多的患者在接受3线既往治疗后疗效不佳。
近几年，双特异性抗体（BsAb）和双靶向CAR-T（CAR-T）细胞已用于复发/难治性多发性骨髓瘤（RRMM）患者；越来越多患者经 3 线既往治疗后仍未能获得有效控制。BCMA/CD3 和 GPRC5D/CD3 是最常见的组合。临床发现显示，患者更可能获得更强且持续时间更长的应答。本文总结 2023 年 ASCO 年会关于靶向 BCMA/CD3、GPRC5D/CD3 的 BsAb 以及 BCMA/CD19 CAR-T 细胞的最新数据。
Bispecific antibodies (BsAbs) and dual-targeted chimeric antigen receptor T (CAR T) cells have been employed in relapsed/refractory multiple myeloma (RRMM) patients over the past few years, as an increasing number of patients were ineffectively treated by 3 prior lines of therapy. BCMA/CD3 and GPRC5D/CD3 are the most popular combinations. Clinical findings indicated that patients exhibit a greater susceptibility to stronger and more enduring responses. Here, we summarize the latest data from the 2023 ASCO annual meeting on BsAbs targeting BCMA/CD3, GPRC5D/CD3 and BCMA/CD19 CAR T cells.
MEMBER ACCOUNT
登录成功会直接打开下一页。
